Publications: Phillips, Elizabeth

Journal Article

Phillips, E., Bartlett, J.A., Sanne, I., Lederman, M.M., Hinkle, J., Rousseau, F., Dunn, D., Pavlos, R., James, I., Mallal, S.A. and Haas, D.W. (2013) Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes, 62 (2). e55-e57.

Phillips, E.J. and Mallal, S.A. (2013) HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS, 27 (3). pp. 491-492.

Rive, C.M., Bourke, J. and Phillips, E.J. (2013) Testing for drug hypersensitivity syndromes. Clinical Biochemist Reviews, 34 (1). pp. 15-38.

Hammond, E., McKinnon, E., Glendenning, P., Williams, R., Mallal, S. and Phillips, E. (2012) Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV. Clinical Endocrinology, 76 (2). pp. 201-206.

Ostrov, D.A., Grant, B.J., Pompeu, Y.A., Sidney, J., Harndahl, M., Southwood, S., Oseroff, C., Lu, S., Jakoncic, J., de Oliveira, C.A.F., Yang, L., Mei, H., Shi, L., Shabanowitz, J., English, A.M., Wriston, A., Lucas, A., Phillips, E., Mallal, S., Grey, H.M., Sette, A., Hunt, D.F., Buus, S. and Peters, B. (2012) Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences, 109 (25). pp. 9959-9964.

Pavlos, R., Mallal, S. and Phillips, E. (2012) HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 13 (11). pp. 1285-1306.

Pavlos, R. and Phillips, E.J. (2012) Individualization of antiretroviral therapy. Pharmacogenomics and Personalized Medicine, 5 (1). pp. 1-17.

Pompeu, Y.A., Stewart, J.D., Mallal, S., Phillips, E., Peters, B. and Ostrov, D.A. (2012) The structural basis of HLA-associated drug hypersensitivity syndromes. Immunological Reviews, 250 (1). pp. 158-166.

Phillips, E.J., Chung, W-H, Mockenhaupt, M., Roujeau, J-C and Mallal, S. (2011) Drug hypersensitivity: Pharmacogenetics and clinical syndromes. Journal of Allergy and Clinical Immunology, 127 (3). S60-S66.

Phillips, E.J. and Mallal, S.A. (2011) HLA-B*1502 Screening and toxic effects of carbamazepine. New England Journal of Medicine, 365 (7). pp. 672-673.

Hertz, T., Nolan, D., James, I., John, M., Gaudieri, S., Phillips, E.J., Huang, J.C., Riadi, G., Mallal, S. and Jojic, N. (2011) Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins. Journal of Virology, 85 (3). pp. 1310-1321.

Haas, D.W., Kuritzkes, D.R., Ritchie, M.D., Amur, S., Gage, B.F., Maartens, G., Masys, D., Fellay, J., Phillips, E., Ribaudo, H.J., Freedberg, K.A., Petropoulos, C., Manolio, T.A., Gulick, R.M., Haubrich, R., Kim, P., Dehlinger, M., Abebe, R. and Telenti, A. (2011) Pharmacogenomics of HIV therapy: Summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clinical Trials, 12 (5). pp. 277-285.

Pirmohamed, M., Friedmann, P.S., Molokhia, M., Loke, Y.K., Smith, C., Phillips, E., La Grenade, L., Carleton, B., Papaluca-Amati, M., Demoly, P. and Shear, N.H. (2011) Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury. Clinical Pharmacology & Therapeutics, 89 (6). pp. 896-901.

Phillips, E.J. and Mallal, S. (2010) Pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 11 (7). pp. 973-987.

Hammond, E., Lucas, A., Lucas, M., Phillips, E. and Gaudieri, S. (2010) Vaniprevir: HCV NS3/4A protease inhibitor treatment of hepatitis C. Drugs of the Future, 35 (10). pp. 803-813.

Phillips, E.J. and Mallal, S. (2009) HLA and drug-induced toxicity. Current Opinion in Molecular Therapeutics, 11 (3). pp. 231-242.

Phillips, E.J. and Mallal, S. (2009) Personalizing antiretroviral therapy: is it a reality? Personalized Medicine, 6 (4). pp. 393-408.

Phillips, E.J. and Mallal, S. (2009) Successful translation of pharmacogenetics into the clinic: The abacavir example. Molecular Diagnosis and Therapy, 13 (1). pp. 1-9.

Chaubey, S.K., Sinha, A.K., Phillips, E., Russell, D.B. and Falhammar, H. (2009) Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection. Sexual Health, 6 (3). pp. 254-257.

Phillips, E., Nolan, D. and Mallal, S. (2008) The Authors reply - Response to Vandekerckhove et al & Abel et al. New England Journal of Medicine, 358 (23). pp. 2515-2516.

Almeida, C.M., Martin, A.M., Nolan, D., Lucas, A., Cameron, P.U., James, I., Phillips, E. and Mallal, S. (2008) Cytokine profiling in abacavir hypersensitivity patients. Antiviral Therapy, 13 (2). pp. 281-288.

Mallal, S., Phillips, E., Carosi, G., Molina, J-M, Workman, C., Tomazic, J., Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J.F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D. and Benbow, A. (2008) HLA-B*5701 screening for hypersensitivity to Abacavir. The New England Journal of Medicine, 358 (6). pp. 568-579.

Saag, M., Balu, R., Phillips, E.J., Brachman, P., Martorell, C., Burman, W., Stancil, B., Mosteller, M., Brothers, C., Wannamaker, P., Hughes, A., Sutherland‐Phillips, D., Mallal, S. and Shaefer, M. (2008) High sensitivity of human leukocyte antigen–B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clinical Infectious Diseases, 46 (7). pp. 1111-1118.

Phillips, E., Hayden, A., Gutiérrez, S., Jahnke, N., Yip, B., Lima, V.D., Hogg, R.S., Harrigan, P.R. and Montaner, J.S.G. (2008) Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: Authorsʼ reply. AIDS, 22 (4). pp. 548-549.

Phillips, E.J. and Mallal, S.A. (2008) Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Current Opinion in Infectious Diseases, 21 (1). pp. 16-24.

Rauch, A., Nolan, D., Thurnheer, C., Fux, C.A., Cavassini, M., Chave, J-P, Opravil, M., Phillips, E., Mallal, S. and Furrer, H. (2008) Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy, 13 (8). pp. 1019-1028.

Shear, N.H., Milpied, B., Bruynzeel, D.P. and Phillips, E.J. (2008) A review of drug patch testing and implications for HIV clinicians. AIDS, 22 (9). pp. 999-1007.

Raboud, J., Lesosky, M., Sterling, S., Phillips, E.J., Walmsley, S. and Bayoumi, A. (2007) An Estimate of the proportion of symptoms reported in Self-administered questionnaires that are captured as adverse drug events in an observational database. HIV Clinical Trials, 8 (5). pp. 311-319.

Phillips, E.J. and Mallal, S. (2007) Drug hypersensitivity in HIV. Current Opinion in Allergy and Clinical Immunology, 7 (4). pp. 324-330.

Martin, A., Almeida, C.M., Cameron, P.U., Purcell, Anthony W, Nolan, D., James, I., McCluskey, J., Phillips, E.J., Landay, Alan and Mallal, S. (2007) Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS, 21 (10). pp. 1233-1244.

Hammond, E., Almeida, C.M., Mamotte, C., Nolan, D., Phillips, E.J., Schollaardt, T.A., Gill, M.J., Angel, J.B., Neurath, D., Li, J., Giulivi, T., McIntyre, C., Koultchitski, G., Wong, B., Reis, M., Rachlis, A., Cole, D., Chew, C.B., Neifer, S., Lalonde, R., Roger, M., Jeanneau, A. and Mallal, S. (2007) External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antiviral Therapy, 12 (7). pp. 1027-1032.

Mallal, S. and Phillips, E. (2007) Introduction of pharmacogenetic screening to HIV clinical practice: Potential benefits and challenges. European Infectious Diseases (2). pp. 13-18.

Nolan, D., Phillips, E. and Mallal, S. (2006) Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance. Clinical Infectious Diseases, 42 (3). pp. 408-410.

Martin, A.M., Krueger, R., Almeida, C.A., Nolan, D., Phillips, E. and Mallal, S. (2006) A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenetics and Genomics, 16 (5). pp. 353-357.

Phillips, E.J., Wong, G., Kaul, R., Shahabi, K., Nolan, D., Knowles, S.R., Martin, A.M., Mallal, S. and Shear, N.H. (2005) Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS, 19 (9). pp. 979-981.

Martin, A.M., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C., Phillips, E., Christiansen, F.T. and Mallal, S. (2005) Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS, 19 (1). pp. 97-99.

Martin, A.M., Nolan, D., Gaudieri, S., Phillips, E. and Mallal, S. (2004) Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics, 5 (6). pp. 643-655.

Martin, A.M., Nolan, D., Gaudieri, S., Almeida, C., James, I., Phillips, E. and Mallal, S. (2004) Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences, 101 (12). pp. 4180-4185.

Conference Item

Phillips, E.J. (2009) Drugs that cause hypersensitivity reactions: Personalising medicine & Predicting the unpredictable. In: Annual Meeting of the American Association of Clinical Chemistry (AACC) 2009, 19 - 23 July 2009, Chicago, IL.

Phillips, E.J. (2009) Overcoming the barrier of clinical translation: The Abacavir example. In: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Conference 2009, 29 November - 2 December 2009, Sydney Convention Centre, Sydney.

Phillips, E.J. (2009) Pharmacogenetic of drug hypersensitivity: Personalising medicine and predicting the unpredictable. In: WAMSG 5th Annual Medication Safety Symposium: ADRs ain'y just ADRs: Action on Adverse Drug Reactions for Medication Safety, 14 July 2009, University Club, University of Western Australia, Crawley.

Lo, G., Herrmann, S., Cheng, W., Kontorinis, N., Phillips, E., Nolan, D. and Lucas, M. (2008) Screening for hepatocellular carcinoma (HCC) in hepatitis/HIV co-infection using ultrasound imaging and alfa-feto protein levels. In: 20th Annual Australasian Society for HIV Medicine Conference, 17 - 20 September, Perth, Western Australia.

Herrmann, S., McKinnon, E., John, M., Nolan, D., Martinez, O.P., Phillips, E. and Mallal, S. (2008) Side effects, dosing schedules, pill burden and perceived stress: interaction and influence on medication. In: 20th Annual Australasian Society for HIV Medicine Conference, 17 - 20 September, Perth, Western Australia.

Martin, A.M., Almeida, C., Nolan, D., Cameron, P., Purcell, A., Chessman, D., McCluskey, J., Phillips, E. and Mallal, S. (2005) Involvement of metabolic and immune responses in the pathogenesis of Abacavir hypersensitivity reaction. In: 17th Annual Conference of the Australasian Society for HIV Medicine (ASHM 2005), 24 - 27 August 2005, Hobart, Tasmania.

Book Chapter

Phillips, E.J. and Mallal, S.A. (2010) Abacavir. In: Wu, A.H.B. and Kiang-Teck, J.Y., (eds.) Pharmacogenomic Testing in Current Clinical Practice. Humana Press, New York, U.S.A, pp. 201-212.

Phillips, E.J. and Mallal, S.A. (2010) HLA and drug reactions. In: Mehra, N.K., Kaur, G., McCluskey, J., Christiansen, F.T. and Claas, F.H.J., (eds.) The HLA Complex in Biology and Medicine: A Resource Book. Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India, pp. 332-349.